Epithelial-mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2014 Dec 18

PMID 25516888

Citations 137

Authors

Arun Satelli

Abhisek Mitra

Zachary Brownlee

Xueqing Xia

Seth Bellister

Michael J Overman

Scott Kopetz

Lee M Ellis

Qing H Meng

Shulin Li

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to detect cell-surface vimentin (CSV) on the surface of epithelial-mesenchymal transitioned (EMT) circulating tumor cells (CTC) from blood of patients with epithelial cancers.

Experimental Design: In this study, 101 patients undergoing postsurgery adjuvant chemotherapy for metastatic colon cancer were recruited. EMT CTCs were detected from blood of patients using the 84-1 monoclonal antibody against CSV as a marker. EMT CTCs isolated were characterized further using EMT-specific markers, fluorescent in situ hybridization, and single-cell mutation analysis.

Results: Using the 84-1 antibody, we detected CSV exclusively on EMT CTCs from a variety of tumor types but not in the surrounding normal cells in the blood. The antibody exhibited very high specificity and sensitivity toward different epithelial cancer cells. With this antibody, we detected and enumerated EMT CTCs from patients. From our observations, we defined a cutoff of <5 or ≥5 EMT CTCs as the optimal threshold with respect to therapeutic response using ROC curves. Using this defined threshold, the presence of ≥5 EMT CTCs was associated with progressive disease, whereas patients with <5 EMT CTCs showed therapeutic response.

Conclusion: Taken together, the number of EMT CTCs detected correlated with the therapeutic outcome of the disease. These results establish CSV as a universal marker for EMT CTCs from a wide variety of tumor types and thus provide the foundation for emerging CTC detection technologies and for studying the molecular regulation of these EMT CTCs.

Citing Articles

Multifaceted Approaches in Epithelial Cell Adhesion Molecule-Mediated Circulating Tumor Cell Isolation.

Szerenyi D, Jarvas G, Guttman A Molecules. 2025; 30(5).

PMID: 40076201 PMC: 11901967. DOI: 10.3390/molecules30050976.

Current biological implications and clinical relevance of metastatic circulating tumor cells.

Shahhosseini R, Pakmehr S, Elhami A, Shakir M, Alzahrani A, Al-Hamdani M Clin Exp Med. 2024; 25(1):7.

PMID: 39546080 PMC: 11567993. DOI: 10.1007/s10238-024-01518-6.

Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.

Sun M, Lu D, Li X, Wang J, Zhang L, Yang P Cancer Med. 2024; 13(18):e70216.

PMID: 39302034 PMC: 11413915. DOI: 10.1002/cam4.70216.

CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.

Portella L, Bertolini G, Guardascione G, Di Febbraro D, Ierano C, DAlterio C Heliyon. 2024; 10(15):e35524.

PMID: 39170328 PMC: 11336720. DOI: 10.1016/j.heliyon.2024.e35524.

Unique Cohorts of Salivary Gland Cancer Cells as an Model of Circulating Tumor Cells.

Mincy C, Revelt L, Carter K, Reed D, Joy A J Maxillofac Oral Surg. 2024; 23(4):896-908.

PMID: 39118911 PMC: 11303642. DOI: 10.1007/s12663-024-02250-0.

References

Pecot C, Bischoff F, Mayer J, Wong K, Pham T, Bottsford-Miller J . A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011; 1(7):580-6. PMC: 3237635. DOI: 10.1158/2159-8290.CD-11-0215. View

Satelli A, Li S . Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011; 68(18):3033-46. PMC: 3162105. DOI: 10.1007/s00018-011-0735-1. View

Parkinson D, Dracopoli N, Petty B, Compton C, Cristofanilli M, Deisseroth A . Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012; 10:138. PMC: 3478228. DOI: 10.1186/1479-5876-10-138. View

Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert A . Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem. 2012; 59(1):252-60. DOI: 10.1373/clinchem.2012.188557. View

Fan F, Samuel S, Evans K, Lu J, Xia L, Zhou Y . Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med. 2013; 1(1):5-16. PMC: 3544430. DOI: 10.1002/cam4.4. View

Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D . Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339(6119):580-4. PMC: 3760262. DOI: 10.1126/science.1228522. View

Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H . Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013; 73(7):2059-69. DOI: 10.1158/0008-5472.CAN-12-0326. View

Bitting R, Boominathan R, Rao C, Kemeny G, Foulk B, Garcia-Blanco M . Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods. 2013; 64(2):129-36. PMC: 3833983. DOI: 10.1016/j.ymeth.2013.06.034. View

Satelli A, Mitra A, Cutrera J, Devarie M, Xia X, Ingram D . Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014; 74(6):1645-50. PMC: 3959622. DOI: 10.1158/0008-5472.CAN-13-1739. View

10.

Bienz M, Clevers H . Linking colorectal cancer to Wnt signaling. Cell. 2000; 103(2):311-20. DOI: 10.1016/s0092-8674(00)00122-7. View

11.

Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart L . Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001; 98(18):10356-61. PMC: 56965. DOI: 10.1073/pnas.171610498. View

12.

Pantel K, Brakenhoff R . Dissecting the metastatic cascade. Nat Rev Cancer. 2004; 4(6):448-56. DOI: 10.1038/nrc1370. View

13.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

14.

Hanley J, McNeil B . The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143(1):29-36. DOI: 10.1148/radiology.143.1.7063747. View

15.

Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T . Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005; 5(9):744-9. DOI: 10.1038/nrc1694. View

16.

Huet D, Bagot M, Loyaux D, Capdevielle J, Conraux L, Ferrara P . SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J Immunol. 2005; 176(1):652-9. DOI: 10.4049/jimmunol.176.1.652. View

17.

Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M . Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer. 2006; 94(12):1816-22. PMC: 2361350. DOI: 10.1038/sj.bjc.6603193. View

18.

Mani S, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N . Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A. 2007; 104(24):10069-74. PMC: 1891217. DOI: 10.1073/pnas.0703900104. View

19.

Yang J, Weinberg R . Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008; 14(6):818-29. DOI: 10.1016/j.devcel.2008.05.009. View

20.

Pierga J, Bidard F, Mathiot C, Brain E, Delaloge S, Giachetti S . Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008; 14(21):7004-10. DOI: 10.1158/1078-0432.CCR-08-0030. View